An Ahmedabad-based in-vitro diagnostics manufacturer plans to raise Rs 203.74 crore via the NSE SME platform
Q-Line Biotech Ltd., an Ahmedabad-based manufacturer, developer, and marketer of in-vitro diagnostics (IVD) reagents, consumables, kits, and diagnostic equipment, opens for subscription on May 21 with the issue closing on May 25. The company is listing on the NSE SME Emerge platform. At Rs 203.74 crore, this is among the largest SME IPOs of the current market cycle and is receiving significant institutional attention.
What the Company Does
Incorporated in 2010 and operational since 2013, Q-Line Biotech develops and manufactures a diverse range of IVD products across five diagnostic segments: Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Rapid Tests. Its annual manufacturing capacity is 1.4 million kits and 1,200 Selectra Machines.
The company also imports and distributes diagnostic equipment from international manufacturers, operating as a one-stop supplier for diagnostic labs, hospitals, and medical colleges. As of March 31, 2026, it had 283 distributors, 103 sales personnel, and 35 service engineers across approximately 26 states and union territories.
The diagnostic sector in India continues to benefit from rising health awareness, growing insurance coverage under Ayushman Bharat, and the expansion of diagnostic labs in tier 2 and tier 3 cities — all of which drive steady long-term demand for IVD products. Q-Line has built its brands over 12 years through R&D, manufacturing, and quality assurance. It raised Rs 61.10 crore from anchor investors ahead of the IPO.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | May 21, 2026 |
| Issue Closes | May 25, 2026 |
| Listing | NSE SME Emerge (May 29, 2026) |
| Price Band | Rs 326 – Rs 343 per share |
| Face Value | Rs 10 |
| Issue Size | Rs 203.74 crore (100% Fresh Issue) |
| Lot Size | 400 shares (min 2 lots = 800 shares) |
| Min. Retail Investment | Rs 2,74,400 |
| Post-IPO Market Cap | Rs 800.16 crore |
| BRLMs | Hem Securities Ltd., Share India Capital Services Pvt. Ltd. |
| Registrar | Purva Sharegistry (India) Pvt. Ltd. |
| Market Maker | Hem Finlease Pvt. Ltd. |
From the fresh issue proceeds, Rs 93.50 crore will go towards working capital, Rs 90 crore towards debt repayment, and the balance for general corporate purposes.
Financial Performance
| Particulars (Rs cr) | FY23 | FY24 | FY25 | 9M FY26 |
|---|---|---|---|---|
| Revenue | 184.81 | 206.45 | 322.58 | 236.50 |
| PAT | 32.10 | 34.44 | 28.13 | 38.69 |
| PAT Margin | 17.56% | 16.92% | 8.97% | 16.65% |
| RoCE | 22.14% | 19.25% | 17.66% | 13.32% |
The revenue growth story is substantial — a 74% jump in FY25 over FY24 reflects real demand growth in IVD products. However, the profit trajectory is more complicated. PAT declined from Rs 34.44 crore in FY24 to Rs 28.13 crore in FY25 despite the strong revenue growth — a margin compression driven by accounting adjustments that pushed the PAT margin from nearly 17% to under 9%.
The 9M FY26 recovery to Rs 38.69 crore in PAT (already exceeding full FY25) and a margin of 16.65% suggests the FY25 setback was partly temporary — but investors should treat the bumper 9M FY26 numbers with appropriate caution given the margin volatility visible across periods. Cash flow from operations has been negative in FY24, FY25, and 9M FY26, driven by working capital expansion and extended credit to customers — an ongoing pressure point.
Risks to Consider
Operating cash flows have been consistently negative for three consecutive periods, meaning the business is consuming cash despite reporting healthy profits — a divergence that raises working capital sustainability questions, particularly post-IPO as the company expands. Total borrowings of Rs 242.57 crore as of December 31, 2025, are substantial for a company of this scale, and while Rs 90 crore from IPO proceeds will reduce this, meaningful leverage will remain. The company has no listed domestic peers, making valuation benchmarking difficult and leaving significant pricing latitude to the management — a structural disadvantage for incoming public investors. RoCE has declined steadily from 22.14% in FY23 to 13.32% in 9M FY26, suggesting the marginal return on capital deployed is falling as the business scales.
Analyst View
Independent analysts note that the company has posted genuine growth in its top lines for the reported periods, but that the FY25 setback in the bottom line following accounting adjustments is a concern. With no listed domestic peers, the company wants a stiff price without a transparent comparable for investors, say analysts. The issue appears fully priced based on its overall financial data point out analysts.